NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free OCUL Stock Alerts $9.10 -0.21 (-2.26%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$9.06▼$9.5050-Day Range$3.85▼$10.9352-Week Range$2.00▼$11.31Volume2.20 million shsAverage Volume2.43 million shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$16.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ocular Therapeutix alerts: Email Address Ocular Therapeutix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside84.6% Upside$16.80 Price TargetShort InterestBearish6.16% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews Sentiment0.98Based on 4 Articles This WeekInsider TradingAcquiring Shares$7 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.04 out of 5 starsMedical Sector217th out of 939 stocksPharmaceutical Preparations Industry95th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.80, Ocular Therapeutix has a forecasted upside of 84.6% from its current price of $9.10.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.16% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Ocular Therapeutix has recently increased by 93.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 3.9 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ocular Therapeutix this week, compared to 3 articles on an average week.Search Interest44 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows20 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 186% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have bought 3,492.29% more of their company's stock than they have sold. Specifically, they have bought $7,000,000.00 in company stock and sold $194,862.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to remain at ($0.68) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 11.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Ocular Therapeutix Stock (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUL Stock News HeadlinesMarch 26, 2024 | globenewswire.comOcular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)March 24, 2024 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.8%March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 22, 2024 | americanbankingnews.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Buy" by AnalystsMarch 21, 2024 | finance.yahoo.comQ4 2023 Clearside Biomedical Inc Earnings CallMarch 19, 2024 | seekingalpha.comOcular Therapeutics' Impressive Surge: A Strategic InsightMarch 17, 2024 | finance.yahoo.comOCUL Apr 2024 12.500 putMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial ProspectsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 13, 2024 | markets.businessinsider.comDecoding 6 Analyst Evaluations For Ocular TherapeutixMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocular Therapeutix on Strong Financials and Promising Pipeline DevelopmentsMarch 12, 2024 | markets.businessinsider.comThese Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 ResultsMarch 12, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 ResultsMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocular Therapeutix on Strong Phase 3 Results and Strategic FocusMarch 11, 2024 | markets.businessinsider.comBalanced Outlook: Hold Rating on Ocular Therapeutix Amidst Trial Progress and Management ChangesMarch 11, 2024 | sfgate.comOcular Therapeutix: Q4 Earnings SnapshotMarch 11, 2024 | finance.yahoo.comOcular Therapeutix Inc Reports Growth Amidst Strategic ShiftsMarch 11, 2024 | globenewswire.comOcular Therapeutix™ Reports Fourth Quarter and Full Year 2023 ResultsMarch 11, 2024 | msn.comBeat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in FocusMarch 10, 2024 | msn.comOcular Therapeutix Q4 2023 Earnings PreviewMarch 10, 2024 | markets.businessinsider.comOcular Therapeutix earnings: here's what Wall Street expectsMarch 8, 2024 | benzinga.comEarnings Outlook For Ocular TherapeutixMarch 5, 2024 | globenewswire.comOcular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024February 28, 2024 | markets.businessinsider.com$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are BuyingFebruary 26, 2024 | markets.businessinsider.comPiper Sandler Maintains Overweight Rating for Ocular Therapeutix: Here's What You Need To KnowFebruary 26, 2024 | markets.businessinsider.comOcular Therapeutix Poised for Growth with Strategic Leadership Hires and Strong Financial PositionFebruary 25, 2024 | investorplace.com3 Stocks to Buy That Are Up 100% or More in 2024See More Headlines Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees267Year FoundedN/APrice Target and Rating Average Stock Price Target$16.80 High Stock Price Target$24.00 Low Stock Price Target$12.00 Potential Upside/Downside+84.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,740,000.00 Net Margins-138.15% Pretax Margin-138.15% Return on Equity-321.12% Return on Assets-53.93% Debt Debt-to-Equity Ratio0.82 Current Ratio6.66 Quick Ratio6.59 Sales & Book Value Annual Sales$58.44 million Price / Sales23.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book11.52Miscellaneous Outstanding Shares148,630,000Free Float140,453,000Market Cap$1.35 billion OptionableOptionable Beta1.32 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Antony Mattessich (Age 56)President, CEO & Director Comp: $1.05MMr. Donald Notman Jr.Chief Financial OfficerDr. Jeffrey S. Heier M.D. (Age 63)Chief Scientific Officer Comp: $84.88kDr. Rabia Gurses Ozden M.D. (Age 56)Chief Medical Officer Comp: $621.39kDr. Pravin U. Dugel M.D. (Age 60)Executive Chairman Dr. Peter K. Jarrett Ph.D. (Age 67)Chief Technology Officer Mr. Philip C. Strassburger Esq. (Age 64)General Counsel Comp: $282.61kMr. William H. Ransone IIVice President of Global Sales & MarketingMs. Tracy SmithVice President of Human ResourcesMr. Christopher G. White (Age 62)Chief Business Officer More ExecutivesKey CompetitorsAkero TherapeuticsNASDAQ:AKRODay One BiopharmaceuticalsNASDAQ:DAWNImmunomeNASDAQ:IMNMAbCellera BiologicsNASDAQ:ABCLProthenaNASDAQ:PRTAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,057,123 shares on 3/11/2024Ownership: 6.444%Trust Co. of VermontBought 1,000 shares on 3/8/2024Ownership: 0.008%Goldman Sachs Group Inc.Sold 27,833 shares on 3/1/2024Ownership: 0.110%Summer Road LlcBought 930,851 shares on 2/26/2024Total: $7.00 M ($7.52/share)Virtu Financial LLCBought 62,066 shares on 2/26/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions OCUL Stock Analysis - Frequently Asked Questions Should I buy or sell Ocular Therapeutix stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUL shares. View OCUL analyst ratings or view top-rated stocks. What is Ocular Therapeutix's stock price target for 2024? 5 analysts have issued 1-year price targets for Ocular Therapeutix's stock. Their OCUL share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $16.80 in the next twelve months. This suggests a possible upside of 84.6% from the stock's current price. View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts. How have OCUL shares performed in 2024? Ocular Therapeutix's stock was trading at $4.46 at the start of the year. Since then, OCUL stock has increased by 104.0% and is now trading at $9.10. View the best growth stocks for 2024 here. When is Ocular Therapeutix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our OCUL earnings forecast. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company earned $12.15 million during the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 321.12% and a negative net margin of 138.15%. During the same quarter in the prior year, the business earned ($0.17) earnings per share. What ETFs hold Ocular Therapeutix's stock? ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (7.64%), Vanguard Group Inc. (6.44%), Vanguard Group Inc. (6.44%), Franklin Resources Inc. (5.67%), Deltec Asset Management LLC (3.08%) and Nuveen Asset Management LLC (1.27%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCUL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.